AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
VAIL, COLO. -- Within the year, American physicians are likely to gain access to an important new type of postmenopausal hormone therapy, Dr. Kenneth Faber said at a conference on obstetrics and gynecology sponsored by the University of Colorado.
Tibolone (Livial) is an intracrine steroid with estrogenic, progestogenic, and androgenic activities depending upon the various end organs at which it is metabolized.
The drug, marketed by Organon in Europe for 10 years, is now being reviewed by the Food and Drug Administration. Based upon clinical trials data as well as the European practice experience, tibolone would appear to offer menopausal women the best ...